--- title: "Why Is SL Science Stock (SLBT) Up Today?" type: "News" locale: "en" url: "https://longbridge.com/en/news/289925899.md" description: "SL Science (SLBT) stock surged over 200% in premarket trading on Tuesday following its Nasdaq debut. The biomedical company went public via a SPAC merger with Horizon Space Acquisition II, valuing SL Bio at approximately $5.57 billion. Management stated the listing aims to enhance access to U.S. capital and support cell therapy programs targeting solid tumors. Despite the rally, analysts note high volatility and lack of coverage as potential risks for investors." datetime: "2026-06-16T13:09:16.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/289925899.md) - [en](https://longbridge.com/en/news/289925899.md) - [zh-HK](https://longbridge.com/zh-HK/news/289925899.md) --- # Why Is SL Science Stock (SLBT) Up Today? SL Science (SLBT) stock underwent a massive rally on Tuesday after the biomedical company's shares started trading on the Nasdaq Global Market under the SLBT ticker on Monday. The company was created after SL Bio combined with special purpose acquisition company (SPAC) Horizon Space Acquisition II. This deal valued SL Bio at about $5.57 billion and was completed alongside a $7.8 million private investment in public equity (PIPE) financing. ### Claim 55% Off TipRanks - Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. - Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter. SL Science claimed this deal added resources needed to advance its cell therapy programs, which target solid tumors such as pancreatic and brain cancers. The company is developing "off-the-shelf" gamma delta T-cell treatments. These seek to reduce the cost and limit the production challenges tied to many current cancer therapies. Management also said the Nasdaq listing should improve access to U.S. capital, support future partnerships, and provide greater flexibility for potential acquisitions. SL Science CEO William Wang said, "Today marks a transformative milestone for the Company as we officially transition to a publicly traded company on Nasdaq." He added that SL Bio aims to bring standardization and scalable manufacturing to the cell therapy market, much like what helped drive growth in the semiconductor industry. ## **SL Science Stock Movement Today** SL Science stock was up 202.1% in premarket trading on Tuesday, following a 42.59% fall yesterday. That's a volatile start to the company's public debut. SL Science stock trading activity was also up today. As of this writing, more than 11 million shares have changed hands. For comparison, nearly 4 million shares changed hands yesterday. ## **Is SL Science Stock a Buy, Sell, or Hold?** Considering just how new SL Science is to the public market, it makes sense that it lacks analyst coverage. That means traders are flying blind when it comes to expert advice on this stock. However, the recent volatility is a red flag. Another potential warning is the use of a SPAC to go public. While this is a completely legitimate way to go public, some companies abuse it as a way to gain a public listing without facing the typical process needed for an initial public offering (IPO) or a direct offering. This isn't to say that SL Science is one of these companies. Instead, it's just something traders should weigh when considering an investment in SLBT stock. ### Related Stocks - [HSPT.US](https://longbridge.com/en/quote/HSPT.US.md) - [SLBT.US](https://longbridge.com/en/quote/SLBT.US.md) ## Related News & Research - [Keen Vision Acquisition faces Nasdaq delisting over SPAC deadline breach, float shortfall](https://longbridge.com/en/news/294417990.md) - [SPAC East West Ave Acquisition prices $100 million IPO, targeting fintech, digital assets, and energy](https://longbridge.com/en/news/294699077.md) - [SPAC TCGX Acquisition prices $75 million IPO, targeting healthcare in Asia](https://longbridge.com/en/news/294969133.md) - [SPAC BOA Acquisition II prices $125 million IPO, targeting real estate and infrastructure](https://longbridge.com/en/news/294826815.md) - [Michael Klein's latest SPAC Churchill Capital Corp XIII prices upsized $360 million IPO](https://longbridge.com/en/news/294516663.md)